



GMDA Summer Meeting
August 6, 2022

Presenter

Swati Gaur, MD, MBA, CMD, AGSF
Medical Director, Alliant Health Solutions




Objectives


- Discuss the latest science pertaining to current existing variants and the level of concern for contagiousness.
- Discuss the current CDC recommendations for the degree of isolation in the general population and infected patients.
- Discuss the currently accepted treatments for COVID and the current recommendations for vaccination.

Current State: COVID-19


The blue bars show daily cases. The red line is the 7-day moving average of cases. The orange line represents the percentage of Emergency Department (ED) visits with diagnosed COVID-19.




Current State: COVID-19



Current State: COVID-19 Among Vaccinated



Resident Cases of COVID-19



Staff Cases of COVID-19



Confirmed COVID-19 Cases among Staff and Rate per 1,000 Resident-Weeks in Nursing Homes, by Week—United States




Display by State

GA

Display by FEMA/HHS Region

All

Cases ☒ Deaths



* Data are likely accruing, all data can be modified from week-to-week by facilities

For the purpose of creating this time-series graph, data that fail certain quality checks or appear inconsistent with surveillance protocols are assigned a value based on their patterns for data-entry or excluded from analysis


Data source: Centers for Disease Control and Prevention, National Healthcare Safety Network

For more information: <https://www.cdc.gov/nhsn/ltc/covid19/index.html>

Accessibility: [Right click on the graph area to show as table]

Data as of 7/25/2022 5:30 AM


Wastewater Surveillance



Current SARS-CoV-2 virus levels by site, United States

Current virus levels category	Num. sites	% sites	Category change in last 7 days
New Site	173	19	0%
0% to 19%	3	0	50%
20% to 39%	55	6	12%
40% to 59%	205	22	- 4%
60% to 79%	340	37	- 14%
80% to 100%	138	15	- 3%

Current COVID-19 Variant




Vaccine Effectiveness: March-June 2022

SARS-CoV-2 infection	3 doses mRNA	69%
Hospitalizations	3 doses mRNA	90%---> 86% for Omicron
ED visit	3 doses mRNA	83%
Mechanical ventilation or death	3 doses mRNA	94%


<https://covid.cdc.gov/covid-data-tracker/#vaccine-effectiveness>

Vaccine Effectiveness in LTC



Crude weekly rates of reported confirmed SARS-CoV-2 infection among skilled nursing facility residents, by vaccination status and resident-week — National Healthcare Safety Network, United States, February 14–March 27, 2022 ([Prasad N, Derado G, Nanduri SA, et al. MMWR 2022;71:633–637](#)).

Effect of 3rd vs 4th Dose Against Omicron



Vaccine Effectiveness Against BA.5

	BA.5		BA.2		OR BA.5 /OR .BA.2 (95% CI)
	Outcome n (%)	Adjusted OR (95%CI)	Outcome n (%)	Adjusted OR (95%CI)	
Hospitalization					
Vaccination status					
Not vaccinated (reference)	9/590 (1.53)	ref	14/631 (2.2)	ref	
Complete primary vaccination	9/2530 (0.36)	0.78 (0.29;2.09)	11/2434 (0.45)	0.38 (0.16;0.89)	2.06 (0.56; 7.55)
1st booster vaccination	34/9186 (0.37)	0.23 (0.10;0.51)	29/12331 (0.24)	0.07 (0.03; 0.14)	3.36 (1.18; 9.63)
Death					
Vaccination status					
Not vaccinated (reference)	8/590 (1.36)	ref	3/631 (0.48)	ref	
Complete primary vaccination	4/2530 (0.16)	0.45 (0.12;1.62)	7/2434 (0.29)	1.00 (0.22;4.08)	0.43 (0.07; 2.73)
1st booster vaccination	15/9186 (0.16)	0.12 (0.04;0.30)	5/12331 (0.04)	0.06 (0.01; 0.24)	1.98 (0.38; 10.36)

Vaccine Effectiveness on Long COVID






Figure 3. Impact of vaccinations on long COVID forest plot.

Effect of Vaccine Mandates on Staffing Shortages



<https://jamanetwork.com/journals/jama-health-forum/fullarticle/2794727>


The Three Pillars



Checklist

- Up-to-date vaccine
 - Residents
 - Staff
- PPE and Infection control:
 - Staff
 - Residents
 - Visitors
- Test early
 - Cohort

Preventing Spread



Therapeutic Considerations

PATIENT DISPOSITION

Does Not Require
Hospitalization or
Supplemental Oxygen

PANEL'S RECOMMENDATIONS

All patients should be offered symptomatic management **(AIII)**.

For patients who are at high risk of progressing to severe COVID-19,^a use 1 of the following treatment options:

Preferred Therapies

Listed in order of preference:

- Ritonavir-boosted nirmatrelvir (Paxlovid)^{b,c} **(AIIa)**
- Remdesivir^{c,d} **(BIIa)**


Alternative Therapies

For use ONLY when neither of the preferred therapies are available, feasible to use, or clinically appropriate. Listed in alphabetical order:

- Bebtelovimab^e **(CIII)**
- Molnupiravir^{c,f} **(CIIa)**

The Panel **recommends against** the use of **dexamethasone^g** or **other systemic corticosteroids** in the absence of another indication **(AIII)**.


Paxlovid: EPIC HR Trial



<https://www.fda.gov/media/158165/download>

<https://www.nejm.org/doi/full/10.1056/NEJMoa2118542>

Remdesivir: PINETREE Trial




Novavax: EUA on July 13, 2022

- **Number of Shots:** Two doses in the primary series, given three to eight weeks apart.
- People who are moderately or severely immunocompromised should also receive two doses, given three weeks apart (a third primary dose is not currently authorized).
- **Booster Shot:** Novavax COVID-19 vaccine is not authorized for use as a booster dose.

Mechanism of action of authorized COVID-19 vaccines


mRNA

Pfizer-BioNTech and Moderna
COVID-19 vaccines




Protein subunit

Novavax COVID-19
vaccine



Viral vector


Janssen/J&J COVID-19 vaccine




Source: https://www.who.int/docs/default-source/coronaviruse/risk-comms-updates/update73_covid-19-vaccines-and-immune-response.pdf?sfvrsn=7902cc35_5

Novavax: Efficacy

Figure 3. Kaplan–Meier Plots of Efficacy of the NVX-CoV2373 Vaccine against Symptomatic Covid-19.



Novavax: Efficacy – Subgroup Analysis





Questions?



Making Health Care Better



@AlliantQIO



@AlliantQIO



Alliant Health Solutions



AlliantQIO

This material was prepared by Alliant Health Solutions, under contract with the Georgia Department of Public Health as made possible through the American Rescue Plan Act of 2021.

quality.allianthealth.org